A Dose Escalating Single Blind Study to Assess the Safety, Tolerability and Pharmacokinetics of a Single Dose of PRS-060 Administered by Oral Inhalation in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 09 Mar 2018
At a glance
- Drugs PRS 060 (Primary) ; PRS 060 (Primary)
- Indications Asthma
- Focus Adverse reactions; First in man
- Sponsors Pieris Pharmaceuticals
- 09 Mar 2018 According to a Pieris Pharmaceuticals media release, the initial results from the study are expected in the fourth quarter of 2018.
- 03 Jan 2018 Status changed from not yet recruiting to recruiting.
- 19 Dec 2017 Status changed from planning to not yet recruiting.